Acies Bio has initiated the construction of a facility that will significantly enhance its fermentation and downstream processing (DSP) capabilities, featuring a groundbreaking 30 m³ bioreactor. This advancement marks a crucial step in the company's efforts to expand its large-scale fermentation and biomanufacturing capabilities, which previously peaked at 10 m³. The investment in this infrastructure is expected to be completed by Q4 2026 and aligns with Acies Bio’s long-term vision of offering flexible biomanufacturing solutions.

At the heart of Acies Bio’s strategy is the principle of flexibility, enabling adaptability across both the value chain and various technology sectors. By integrating advanced biomanufacturing capacity with its existing R&D and pilot-scale infrastructure, Acies Bio is positioning itself to deliver comprehensive biomanufacturing services throughout Europe. “Europe needs flexible biomanufacturing infrastructure that can bridge the gap between innovation and commercialization,” stated Štefan Fujs, CEO of Acies Bio. He emphasized that emerging bio-based technologies necessitate customized solutions and technical expertise to achieve rapid market readiness, and this expansion will bolster Acies Bio's role in supporting Europe’s bioeconomy.

In line with this vision, Acies Bio aims to serve as a reliable partner for companies navigating the complexities of bioprocess optimization, scale-up, and market entry. The new facility will empower innovators to transform laboratory discoveries into scalable, compliant, and competitive biomanufacturing solutions. “This is a major step forward for Acies Bio’s technical capabilities,” remarked Mirjan Švagelj, Director of Bioprocessing at Acies Bio. He noted that the introduction of the 30 m³ bioreactor, along with new 8 m³ and 3 m³ systems, will double their fermentation capacity to 72 m³, enhancing throughput and enabling the company to handle more complex and larger-scale projects.

Acies Bio's biomanufacturing services are backed by two decades of in-house R&D expertise, which helps partners achieve significant improvements in yield, productivity, and cost efficiency. This iterative approach facilitates ongoing reductions in cost of goods sold (COGS) and process optimization, turning each production campaign into an opportunity for further enhancement and competitive advantage. This was exemplified by Acies Bio’s collaboration with Plant Health Care, a leading provider of biological products for sustainable agriculture. "We value Acies Bio’s reliability and technical rigor throughout the biomanufacturing process,” said Meagan Osborn, Head of Supply Chain at Plant Health Care. “Their integrated approach has proven effective in meeting our performance targets and maintaining consistent quality at scale.”

With this expansion, Acies Bio reaffirms its commitment to advancing flexible biomanufacturing in Europe, equipping the industry with the infrastructure, expertise, and partnerships necessary to accelerate the shift toward a sustainable bio-based future.